Table 1.
Study flowchart.
| Time point | From day 30 to day 1 | Day 1 | Day 7±1 day | Months 3±7 days | Day 111±7 days | Months 6±7 days |
| Visit denomination | Screening | V1 | V2 | V3 | V3bis in case of recurrent AKa | V4 |
| Visit type | Screening | Treatment | Evaluation | Evaluation | Treatment | Evaluation |
| Informed consent | ✓b | —c | — | — | — | — |
| Medical history | ✓ | — | — | — | — | — |
| Check of inclusion and exclusion criteria | ✓ | — | — | — | — | — |
| Documentation of AK including location, number, and grade | — | ✓ | — | ✓ | ✓ | ✓ |
| Photo-documentation of AK | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Separation of AK in 2 areas | — | ✓ | — | — | — | — |
| Randomization | — | ✓ | — | — | — | — |
| Pain score during treatment | — | ✓ | — | — | ✓ | — |
| Adverse effects/reactions | — | — | ✓ | — | — | — |
| Skin appearance/cosmetic outcome | — | — | — | ✓ | — | ✓ |
| Completion of the Dermatology Life Quality Index | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Completion of the satisfaction questionnaire | — | ✓ | ✓ | ✓ | ✓ | ✓ |
| Documentation of adverse events and serious adverse events | — | ✓ | — | ✓ | ✓ | ✓ |
| Pregnancy test | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
aAK: actinic keratosis.
bIndicates during which visits the actions reported in the first column were performed.
cIndicates that the corresponding action was not performed at the considered visit.